COO · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The business does not meet the quality standard for its economic type.
At $76.82, COO requires a 6% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 6%.
The live dispute is organic revenue growth — six consecutive organic-guidance cuts and the myopia-management modality question — not margin.
The conditions that would settle the disagreement are dated to September 2026.
The value rests on an exit multiple of 19.1x, a terminal operating margin of 19% and a 7.1% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The myopia-management franchise loses the modality, and the fertility franchise's recall exposure exceeds its accrual.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The live dispute is organic revenue growth — six consecutive organic-guidance cuts and the myopia-management modality question — not margin. |
| What do we forecast? | Revenue growth of 6% demonstrated; a terminal operating margin of 19%; an exit multiple of 19.1x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +0.1 percentage points. |
| What is it worth? | Twelve-month target $90.00, +17% from the struck price. Scenario-weighted expected return net of costs +17.2%. |
| Why now? | The first dated test of the thesis falls on 9 September 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 9 September 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| 9 September 2026 | FY2026 organic guidance cut below 3.5% at the FQ3-26 or FQ4-26 print… | FY2026 organic guidance cut at or above 3.5% at the FQ3-26 or FQ4-26 print, and initial FY2027 organic guidance issued… | FY2026 organic guidance cut below 3.5% at the FQ3-26 or FQ4-26 print, OR initial FY2027 organic guidance issued below… |
| quarterly from FQ3-26 | CooperVision organic revenue growth below 3.0% in two consecutive… | CooperVision organic revenue growth at or above 3.0% in two consecutive quarters | CooperVision organic revenue growth below 3.0% in two consecutive quarters |
| quarterly from FQ3-26 | Non-GAAP gross margin below 66.0% for two consecutive quarters — the… | Non-GAAP gross margin at or above 66.0% for two consecutive quarters | Non-GAAP gross margin below 66.0% for two consecutive quarters |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
The myopia-management franchise loses the modality, and the fertility franchise's recall exposure exceeds its accrual. Mechanism, four independent records already in this folder: the FDA PMA history shows 34 MiSight supplements in 6.7 years with zero indication expansions while the Biofinity PMA took at least nine in the same window; there is no US regulatory record at all for MyDay MiSight; PubMed publication share for DIMS spectacle lenses crossed MiSight in 2024 and now runs ~5x it; and CooperVision's own registry study is of COMPETITORS' spectacle lenses. Management said it out loud on the FQ2 call: 'Glasses are doing incredibly well around the world. But that is a short-term negative for us.
Estimated probability 20%, against the 21% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim on approach to $90.00 (the 12-month target). MANDATORY valuation reassessment at 5.089x EV/NTM revenue — the 3-year median of COO's own forward-sales history — which is ~$105 at consensus NTM revenue. On approach to the $90.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The myopia-management franchise loses the modality, and the fertility franchise's recall exposure exceeds its accrual. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +0.1 percentage points more growth than the price requires. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the test dated 9 September 2026, or a daily close below $67.60, which forces an immediate review.